ArticleFrontiers in pharmacology2021
Antiviral and Immunomodulatory Effects of
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review.Frontiers in pediatrics · 2025Pooled it
- Randomised, Placebo-Controlled, Double-Blind Trial to Assess Efficacy and Safety of ELOM-080 in Outpatients with COVID-19.Advances in therapy · 2025Trial
- The efficacy and safety of DW1601 in patients with acute bronchitis: a multi-center, randomized, double-blind, phase III clinical trial.The Korean journal of internal medicine · 2022Trial
- Protective effects of Pelargonium sidoides against oxidative stress and inflammation in experimental mesenteric ischemia-reperfusion injury.Journal of molecular histology · 2026Article
- Immunomodulating effects of herbal cough medication - in vitro screening in a TLR7- and TLR8-mediated inflammatory model.BMC complementary medicine and therapies · 2026Article
- Broad-spectrum host-targeting antivirals for rhinovirus infections: mechanisms and future perspectives.Frontiers in immunology · 2026Review
- Immunomodulatory Effects ofExpert reviews in molecular medicine · 2025Review
- Prescription of EPs 7630 is associated with short- and long-term benefits in acute bronchitis: a real-world data analysis.Frontiers in pharmacology · 2025Article
- Unlocking the therapeutic potential ofHeliyon · 2024Article
- Identifying in-market application of Pelargonium root extract EPs 7630 for the treatment of COVID-19: analysis of pharmacovigilance data.Frontiers in pharmacology · 2024Article
- Long-term benefits of EPsFrontiers in pharmacology · 2024Article
- Hand, foot, and mouth disease: could EPs® 7630 be a treatment option? A prospective randomized open-label multicenter clinical study.Frontiers in pediatrics · 2024Article
- Multiple mechanisms enable broad-spectrum activity of theFrontiers in pharmacology · 2024Review
- EPsInternational journal of molecular sciences · 2023Article
- Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2.Viruses · 2023Article
- Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysis.Multidisciplinary respiratory medicine · 2023Article
- Article
- Safety ofFrontiers in pediatrics · 2023Article
- Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases of COVID-19: A Hypothetical Approach.Advances in experimental medicine and biology · 2023Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for COVID-19 are currently limited. Drugs reducing both viral loads and SARS-CoV-2-induced inflammatory responses would be ideal candidates for COVID-19 therapeutics. Previous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.